Gotowa bibliografia na temat „5'-nucleotidase”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „5'-nucleotidase”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "5'-nucleotidase"
Olsson, Ray A. "CardiovascularEcto-5′-Nucleotidase". Circulation Research 95, nr 8 (15.10.2004): 752–53. http://dx.doi.org/10.1161/01.res.0000146278.94064.4b.
Pełny tekst źródłaRees, David C., John A. Duley i Anthony M. Marinaki. "Pyrimidine 5′ Nucleotidase Deficiency". British Journal of Haematology 120, nr 3 (luty 2003): 375–83. http://dx.doi.org/10.1046/j.1365-2141.2003.03980.x.
Pełny tekst źródłaItoh, Roichi. "IMP-GMP 5′-nucleotidase". Comparative Biochemistry and Physiology Part B: Comparative Biochemistry 105, nr 1 (maj 1993): 13–19. http://dx.doi.org/10.1016/0305-0491(93)90163-y.
Pełny tekst źródłaPiec, G., i M. Le Hir. "The soluble ‘low-Km’ 5′-nucleotidase of rat kidney represents solubilized ecto-5′-nucleotidase". Biochemical Journal 273, nr 2 (15.01.1991): 409–13. http://dx.doi.org/10.1042/bj2730409.
Pełny tekst źródłaDarvish, A., R. W. Pomerantz, P. G. Zografides i P. J. Metting. "Contribution of cytosolic and membrane-bound 5'-nucleotidases to cardiac adenosine production". American Journal of Physiology-Heart and Circulatory Physiology 271, nr 5 (1.11.1996): H2162—H2167. http://dx.doi.org/10.1152/ajpheart.1996.271.5.h2162.
Pełny tekst źródłaPanteghini, M. "Electrophoretic fractionation of 5'-nucleotidase". Clinical Chemistry 40, nr 2 (1.02.1994): 190–96. http://dx.doi.org/10.1093/clinchem/40.2.190.
Pełny tekst źródłaÖzsoylu, Şinasi. "About Pyrimidine 5’-Nucleotidase Deficiency". Turkish Journal of Hematology 30, nr 2 (5.06.2013): 227. http://dx.doi.org/10.4274/tjh.2013.0050.
Pełny tekst źródłaHansen, Thor Willy Ruud, Martin Seip, Carl-Henric Verdier i ÅKe Ericson. "Erythrocyte Pyrimidine 5‘-Nucleotidase Deficiency". Scandinavian Journal of Haematology 31, nr 2 (24.04.2009): 122–28. http://dx.doi.org/10.1111/j.1600-0609.1983.tb01518.x.
Pełny tekst źródłaRamaswamy, S. G., i W. B. Jakoby. "(2')3',5'-Bisphosphate nucleotidase." Journal of Biological Chemistry 262, nr 21 (lipiec 1987): 10044–47. http://dx.doi.org/10.1016/s0021-9258(18)61072-5.
Pełny tekst źródłaColaco, Camilo A. L. S. "Potocytosis, 5′-nucleotidase and transport". Trends in Cell Biology 2, nr 8 (sierpień 1992): 223. http://dx.doi.org/10.1016/0962-8924(92)90299-3.
Pełny tekst źródłaRozprawy doktorskie na temat "5'-nucleotidase"
SIEGFRIED, GERALDINE. "Modulation de l'activite 5'-nucleotidase tubulaire renale". Paris 7, 1996. http://www.theses.fr/1996PA077134.
Pełny tekst źródłaRoever, Lisa. "Inhibitor Studies for 5’-ecto-nucleotidase (CD73)". Ohio University / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=ohiou1553892946798977.
Pełny tekst źródłaZanin, Rafael Fernandes. "Investigação das ectonucleotidases na diferenciação de macrófagos e na ativação de plaquetas : o papel da homocisteína". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2010. http://hdl.handle.net/10183/61004.
Pełny tekst źródłaExtracellular nucleotides modulate a variety of biological actions via purinergic receptor activation. These effects are modulated by ectonucleotidases, such as ENTPDases and ecto-5´- NT/CD73, which hydrolyze ATP to adenosine in the extracellular milieu. In the cells of the immune system, the ATP can act as danger signaling whereas adenosine, the ATP breakdown product, serves as a negative feedback mechanism to limit inflammation. Already, in the vasculare system, the ADP is a physiological agonist involved in normal hemostasis and thrombosis. Since, macrophages are key to inflammatory process, that depending on the microenvironmental stimulation exhibit proinflammatory/ defense (classical/M1) and antiinflammatory/reparatory (alternative/M2) phenotype. The objective of this study was investigate the activity and expression of the ectonuclotidases in differential macrophage phenotype and evaluate the homocysteine (Hcy) effects on theses enzymes in macrophages and platelets. . The analysis of differential macrophages in phenotype proinflamatory/ M1 and antiinflamatory/M2 showed the same expression to P1 and P2 purinoreceptors. However, change profile of the ectonucleotidases as E-NTPDase1, E-NTPDase3 and ecto-5’- nucleotidase enzymes in macrophages during phenotypic differentiation were found, suggesting that macrophages must alter the purinergic cascade during macrophages differentiation phenotypic. In the pro-inflamatory/M1 phenotype the ATP hydrolysis decreased, suggesting ATP accumulation. On the other hand, the antiinflamatory/M2 phenotype the enzymes lead to a progressive decrease in nucleotides (ATP) concentrations and an increase the adenosine availability. Already, the macrophages exposed to Hcy present a polarized pro-inflammatory profile (M1) and our findings suggest the involvement of the E-NTPDase3 and ecto-5’-nucleotidase in the inflammatory complications associates to homocysteine. In the Platelets, which are fundamental elements to the thrombogenesis process, the homocysteine decreased ADP hydrolysis. This elevation of ADP around of the platelets due inactivating of ectonucleotidase, probably by the indirect action of Hcy, may be contributing to increase thrombotic risk described in individuals with hyperhomocysteinemia. In addition, the animals that received Hcy treatment potentiate platelet aggregation induced by ADP. In conclusion, in the present study the results reinforce purinergic signaling involvement in inflammatory/thrombosis process and point to development of treatments to inflammatory/thrombotic diseases.
Bavaresco, Luci. "Estudo do papel da ecto-5'-nucleotidase/CD73 na proliferação de gliomas". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2008. http://hdl.handle.net/10183/12713.
Pełny tekst źródłaMalignant gliomas are the most common and devastating primary tumors in the central nervous system. Despite treatment, patients with these tumors have a poor prognosis. Ecto-5‟-nucleotidase/CD73 (ecto-5‟-NT/CD73) may regulate the extracellular AMP and adenosine levels, which have been described as proliferation factor. The participation of ecto-5‟-NT/CD73 per se has been proposed as a proliferative factor, being involved in the control of cell growth, maturation, differentiation, invasion, migration and metastases processes. In the present study, we evaluate the ecto-5‟-NT/CD73 activity and functions in rat C6 and human U138-MG glioma cell lines proliferation process. Crescent confluences and culture times leads to an increase on ecto-5‟-NT/CD73 activity in both C6 and U138-MG glioma cells. RT-PCR analysis and flow cytometry showed a significant increase on ecto-5‟-NT/CD73 mRNA and protein levels respectively, when compared confluent cultures with subconfluent one in human U138-MG glioma cells. Treatment with 1 M APCP, a competitive ecto-5‟-NT inhibitor, caused a significant reduction in glioma cell proliferation of 20% for U138-MG glioma cell line. In addition, 100 M adenosine increases cell proliferation in 25% and AMP 1m M and 3 mM decrease U138-MG glioma cells proliferation in 29% and 42% respectively. The stable silencement of ecto-5‟-NT/CD73 by RNAi technique reduces cell migration in human U138-MG glioma cell line. Taken together these results suggest the participation of ecto-5‟-NT/CD73 in cell proliferation, being this process dependent of enzymatic activity generating adenosine, a proliferative factor and removing toxic levels of AMP, as well as a function as adhesive molecule.
ZEKRI, MUSTAPHA. "Heterogeneite structurale et fonctionnelle de la 5-nucleotidase". Nantes, 1990. http://www.theses.fr/1990NANT2056.
Pełny tekst źródłaKnöfel, Thomas. "Röntgenstrukturanalyse der 5'-Nucleotidase aus Escherichia coli mit dinuklearem Metallzentrum". [S.l. : s.n.], 2000. http://www.diss.fu-berlin.de/2000/131/index.html.
Pełny tekst źródłaOsborne, Foy Naomi. "Over-Expression of Ecto-5'-Nucleotidase in Pig Endothelial Cells". Thesis, Imperial College London, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.487200.
Pełny tekst źródłaMcMillen, Lyle, i l. mcmillen@sct gu edu au. "Isolation and Characterisation of the 5'-Nucleotidase from Escherichia coli". Griffith University. School of Biomolecular and Biomedical Science, 2001. http://www4.gu.edu.au:8080/adt-root/public/adt-QGU20030226.153545.
Pełny tekst źródła黎錦明 i Kam-ming Lai. "Structure and function of 5'-nucleotidase of the rat brain". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1991. http://hub.hku.hk/bib/B31232280.
Pełny tekst źródłaEristi, Can M. "Investigation of Transcriptional Regulation of 5'-Nucleotidase in Dictyostelium Discoideum". Diss., Virginia Tech, 2003. http://hdl.handle.net/10919/28822.
Pełny tekst źródłaPh. D.
Książki na temat "5'-nucleotidase"
Barber, Ian Stuart. 5'-nucleotidase: It's [sic]Membrane/cytoskeletal associations. Birmingham: Universityof Birmingham, 1989.
Znajdź pełny tekst źródłaMarani, Enrico. Topographic histochemistry of the cerebellum: 5'-nucleotidase, acetylocholinesterase, immunology of FAL. Stuttgart: G. Fischer Verlag, 1986.
Znajdź pełny tekst źródłaCzęści książek na temat "5'-nucleotidase"
Schomburg, Dietmar, i Margit Salzmann. "5’-Nucleotidase". W Enzyme Handbook 3, 309–14. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-76463-9_66.
Pełny tekst źródłaFroehlich, Stephan J., Carlo A. Lackerbauer, Guenter Rudolph, Jan Rémi, Soheyl Noachtar, Werner J. Heppt, Annette Cryer i in. "5′-Nucleotidase Hyperactivity". W Encyclopedia of Molecular Mechanisms of Disease, 1501–2. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-29676-8_4.
Pełny tekst źródłaBraun-Falco, Markus, Henry J. Mankin, Sharon L. Wenger, Markus Braun-Falco, Stephan DiSean Kendall, Gerard C. Blobe, Christoph K. Weber i in. "Pyrimidine 5′ Nucleotidase Deficiency". W Encyclopedia of Molecular Mechanisms of Disease, 1798. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-29676-8_8047.
Pełny tekst źródłaBraun-Falco, Markus, Henry J. Mankin, Sharon L. Wenger, Markus Braun-Falco, Stephan DiSean Kendall, Gerard C. Blobe, Christoph K. Weber i in. "Pyrimidine 5′ Nucleotidase-1 Deficiency". W Encyclopedia of Molecular Mechanisms of Disease, 1798. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-29676-8_8048.
Pełny tekst źródłaKreutzberg, G. W., D. Heymann i M. Reddington. "5′-Nucleotidase in the Nervous System". W Proceedings in Life Sciences, 147–64. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-70664-6_11.
Pełny tekst źródłaMarinello, E., A. Tabucchi, F. Carlucci, P. Galieni i F. Rosi. "Isoenzymes of 5′-Nucleotidase in Human Lymphocytes". W Advances in Experimental Medicine and Biology, 555–58. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5381-6_107.
Pełny tekst źródłaWebster, A. D. B., M. Rowe, S. M. Johnson, G. L. Asherson i A. Harkness. "Ecto 5′-Nucleotidase Deficiency in Primary Hypogammaglobulinaemia". W Ciba Foundation Symposium 68 - Enzyme Defects and Immune Dysfunction, 135–64. Chichester, UK: John Wiley & Sons, Ltd., 2008. http://dx.doi.org/10.1002/9780470720516.ch9.
Pełny tekst źródłaTozzi, M. G., M. Camici, S. Allegrini, R. Pesi, M. Turriani, A. Del Corso i P. L. Ipata. "Cytosolic 5′-Nucleotidase/Phosphotransferase of Human Colon Carcinoma". W Advances in Experimental Medicine and Biology, 173–76. New York, NY: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-7703-4_39.
Pełny tekst źródłaYamazaki, Y., A. R. Collinson, V. L. Truong i J. M. Lowenstein. "Regulation of Soluble 5′-Nucleotidase I from Rabbit Heart". W Advances in Experimental Medicine and Biology, 107–11. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4684-5676-9_17.
Pełny tekst źródłaBontemps, F., G. Van den Berghe i H. G. Hers. "Identification of a Purine 5′-Nucleotidase in Human Erythrocytes". W Purine and Pyrimidine Metabolism in Man V, 283–90. New York, NY: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-1248-2_45.
Pełny tekst źródłaStreszczenia konferencji na temat "5'-nucleotidase"
Nguyen, Anna M., Jianhong Zhou i Yuchun Du. "Abstract B05: Ecto-5’-nucleotidase (CD73) confers radioresistance in pancreatic cancer". W Abstracts: AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; May 12-15, 2016; Orlando, FL. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.panca16-b05.
Pełny tekst źródłaJordheim, Lars P., Zsuzsanna Marton, Moez Rhimi, Laurent Chaloin, Emeline Cros-Perrial, Corinne Lionne, Suzanne Peyrottes, Nushin Aghajari i Charles Dumontet. "Abstract 3835: Identification and characterization of inhibitors of 5′-nucleotidase cN-II issued from virtual screening". W Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3835.
Pełny tekst źródłaBowser, Jessica L., Michael R. Blackburn, Gregory L. Shipley, Susu Xie i Russell R. Broaddus. "Abstract 3384: Down-regulation of 5’-nucleotidase (CD73)-generated adenosine: A novel mechanism for regulating endometrial cancer metastasis". W Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3384.
Pełny tekst źródłaMatsuyama, Masahiro, Masatoshi Wakui, Makoto Monnai, Tomoko Mizushima, Chiyoko NIshime, Kenji Kawai, Hiroshi Suemizu i in. "Abstract 2366: Reduced ecto-5′-nucleotidase CD73 expression and altered purine nucleotide metabolism in colorectal cancer cells robustly causing liver metastases". W Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2366.
Pełny tekst źródłaZborovsky, AB, BV Zavodovsky, EV Bobicheva, LE Sivordova i NA Fofanova. "THU0055 Role of antibodies to 5’nucleotidase in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, ankylosing spondylarthritis and reactive arthritis patients". W Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.899.
Pełny tekst źródłaZborovsky, AB, BV Zavodovsky, TA Pankratova, AV Rvachev, OV Bykova i TV Serdukova. "SAT0001 Role of determination of succinate dehydrogenase, myeloperoxidase, na ± k ± atph-ase, 5?-nucleotidase in cells of peripheral blood of ankylosing spondylarthritis patients". W Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.353.
Pełny tekst źródłaGoueli, Said A., i Kevin hsiao. "Abstract 414: Biochemical and cellular monitoring of the activity of the ecto-5’-nucleotidase (CD73), a key cancer modulator using HTS-formatted bioluminescent technology". W Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-414.
Pełny tekst źródła